Amycretin could give Novo a buzzy product in a newly competitive obesity market. It works similarly to existing GLP-1 ...
TD Cowen analyst Michael Nedelcovych maintained a Buy rating on Novo Nordisk (NVO – Research Report) today. The company’s shares closed ...
Hosted on MSN1mon
A next-gen Ozempic falls short in a drug trial — and Novo Nordisk stock plunges 20%The logo of Danish pharmaceutical company Novo Nordisk is pictured at their headquarters in Bagsvaerd outside of Copenhagen, Denmark on February 1, 2017. Novo Nordisk (NVO) released mixed clinical ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback